NanoLogix, Inc. is a biotechnology / genomics company owning 31 issued patents with applications in nanotechnology, hydrogen gas production, medical drugs/devices, bio-defense sensors and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems (“BioMEMS”) for rapid environmental microbial monitoring with bio-defense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources.
NanoLogix’s FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease-producing bacteria, including Tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery.
Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water.
. |
